Skip to content

Contact +44 (0) 20 7060 7474 email us

Asia / Pacific

The Asian Cardiovascular Market Outlook to 2014

Regional and therapeutic analysis, pipeline impact and growth opportunities

Publication Date March 2009
Publisher Business Insights
Product Type Report
Pages 244
ISBN Number not applicable
Product Code RBI00194

Price

£2,025.00
approximately: $3,066 | €2,260

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The Asian cardiovascular market demonstrated robust sales, unlike the global market which has begun to slow down due to patent expiries of class leading products and strong generic competition. The emerging ten Asian markets analyzed in this report is a mixture of developed nations like South Korea, Taiwan, Hong Kong, Singapore and Malaysia, and developing markets such as China, India, Thailand, Philippines and Indonesia. Although these markets have lower healthcare expenditure per head compared to the US and EU, the Asian markets are regarded as the potential growth markets of the health services industry and consequently the pharmaceutical sector. The market is also being driven by the shift of focus from primary care to specialty care. In comparison to the western markets drug patent expiries minimally affect proprietary brand growth dynamics in Asia. Regional customization of brand prices and aggressive marketing strategies have positioned branded drugs in direct competition with generic brands.

Contents

  • The Asian cardiovascular market outlook to 2014
  • Executive Summary
  • Patient potential
  • Regional healthcare and licensing trends
  • Regional market analysis
  • Key players in the Asian cardiovascular market
  • Chapter 1 Scope and methodology
    • Scope
    • Key CV sub-therapy areas covered in this report
    • Methodology
  • Chapter 2 Patient potential
    • Summary
    • Introduction
    • Disease description
    • Defining patient potential
    • Limitations of cardiovascular epidemiology data
    • Cardiovascular risk factors
    • Hypertension
    • Dyslipidemia
    • Diabetes
    • Cardiovascular disease
    • Acute thrombotic events
    • Acute coronary syndrome
    • Venous thromboembolism
    • Stroke
  • Chapter 3 Regional healthcare and licensing trends
    • Summary
    • Introduction
    • Regional healthcare expenditure
    • Healthcare financing
    • The external environment
    • Licensing analysis
  • Chapter 4 Regional market analysis
    • Summary
    • Introduction
    • Leading cardiovascular therapy areas
    • Leading Asian cardiovascular markets
    • Leading cardiovascular brands
    • Antihypertensives
    • Introduction
    • Leading antihypertensive brands
    • Regional dynamics
    • Market analysis by drug class
    • Calcium channel blockers: driven by replacability
    • Angiotensin receptor blockers: driven by efficacy
    • ACE inhibitors: downplayed by side effects
    • Beta-blockers: driven by pricing
    • Diuretics: outdated and stabilizing
    • Antihypertensives sales forecasts
    • Anti-dyslipidemics
    • Introduction
    • Leading anti-dyslipidemic brands
    • Regional dynamics
    • Market analysis by drug class
    • Statins: irreplacable dominance
    • Fibrates: outdated
    • Other anti-dyslipidemics
    • Anti-dyslipidemics sales forecast
    • Cardiac therapies
    • Introduction
    • Leading cardiac therapy brands
    • Market analysis by drug class
    • Nitrates/nitrites: driven by pricing
    • Anti-arrhythmics: overcome by nitrates
    • Others
    • Cardiac therapies sales forecasts
    • Anti-thrombotics
    • Introduction
    • Leading anti-thrombotic brands
    • Regional dynamics
    • Market analysis by drug class
    • Heparins/low molecular weight heparins: overshadowed by antiplatelets
    • Vitamin K antagonists: outdated
    • Oral anti-platelets: preventive advantage drives sales
    • Fibrinolytics: driven by emergency care demands
    • Anti-thrombotic sales forecasts
  • Chapter 5 Key players in the Asian cardiovascular market
    • Summary
    • Introduction
    • Key events and trends
    • Global CV research affected by ipitorphobia'; diffused impact on Asia
    • From a single wheeled to multi-wheeled structure: reducing dependence on the CV sector, target Asia
    • HDL mimetics will minimally drive the Asian market
    • Asian market shares
    • Pfizer: contemplating a paradigm shift
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Apixaban
    • Cardiovascular portfolio sales forecasts
    • Sanofi-Aventis
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Multaq
    • Cardiovascular portfolio sales forecasts
    • AstraZeneca
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Ticagrelor
    • Cardiovascular portfolio sales forecasts
    • Novartis
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Tekturna
    • Cardiovascular portfolio sales forecasts
    • Merck & Co
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Anacetrapib
    • Cardiovascular portfolio sales forecasts
    • Bayer
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline: Xarelto to capture Lovenox market
    • Xarelto
    • Cardiovascular portfolio sales forecasts
    • GSK
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Letairis
    • Cardiovascular portfolio sales forecasts
    • Servier
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Cardiovascular portfolio sales forecasts
    • Roche
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Dalcetrapib
    • Cardiovascular portfolio sales forecasts
    • Boehringer Ingelheim
    • Country focus
    • Therapy focus
    • Key brands
    • Pipeline
    • Cardiovascular portfolio sales forecasts
    • Forecast rankings of the key players, 2014
  • Chapter 6 Appendix
    • IMS Data
    • C1 Cardiac therapy
    • C2 Antihypertensives
    • C3 Diuretics
    • C4 Cerebral and peripheral vasotherapeutics
    • C5 Antivaricosis/anti-haemorrhoidal preparations
    • C6 Other cardiovascular products
    • C7 Beta-blocking agents
    • C8 Calcium antagonists
    • C9 Agents acting on the renin-angiotensin system
    • C10 Lipid-regulating/anti-atheroma preparations
    • C11 Cardiovascular multitherapy combination products
    • B1 Anti-thrombotic agents
    • B2 Antifibrinolytics, antidotes to anti-coagulants, inhibitors, blood coagulation and haemostyptics
    • B3 Anti-anaemic preparations
    • B6 All other haematological agentsGlossary
    • Glossary
    • Index
  • List of Figures
    • Figure 2.1: Relationship between CV disease and risk factors
    • Figure 2.2: Risk factors associated with hypertension
    • Figure 3.3: External analysis of the Asian region
    • Figure 3.4: Asian CV licensing trends, 2007
    • Figure 4.5: Competitive dynamics of therapy areas in the Asian CV market,
    • Figure 4.6: Competitive dynamics of the 10 major Asian markets,
    • Figure 4.7: Competitive dynamics of the Asian antihypertensive market by drug class, 2006-07
    • Figure 4.8: Regional dynamics of the Asian antihypertensive market, 2006-07
    • Figure 4.9: Regional dynamics of the Asian CCB market, 2006-07
    • Figure 4.10: Regional dynamics of the Asian ARB market, 2006-07
    • Figure 4.11: Regional dynamics of the Asian ACE inhibitor market, 2006-07
    • Figure 4.12: Regional dynamics of the Asian beta-blocker market, 2006-07
    • Figure 4.13: Regional dynamics of the Asian diuretics market, 2006-07
    • Figure 4.14: Competitive dynamics in the Asian anti-dyslipidemics market, 2006-07
    • Figure 4.15: Regional dynamics of the Asian anti-dyslipidemics market, 2006-07
    • Figure 4.16: Regional dynamics of the Asian statins market, 2006-07
    • Figure 4.17: Regional dynamics of the Asian fibrate market, 2006-07
    • Figure 4.18: Competitive dynamics in the Asian cardiac therapies market by drug class, 2006-07
    • Figure 4.19: Regional dynamics of the Asian cardiac therapies market, 2006-07
    • Figure 4.20: Competitive dynamics in the Asian anti-thrombotic market by drug class, 2006-07
    • Figure 4.21: Regional dynamics of the Asian anti-thrombotics market, 2006-07
    • Figure 5.22: Big Pharma's strategy for the future
    • Figure 5.23: Competitive dynamics of key players in the Asian CV market, 2006-07
    • Figure 5.24: Focus therapy areas and revenue shares of Pfizer, 2007
    • Figure 5.25: Major events/trends in Pfizer's forcasted growth dynamics
    • Figure 5.26: Focus therapy areas and revenue shares of Sanofi-Aventis, 2007
    • Figure 5.27: Major events/trends in Sanofi-Aventis's forcasted growth dynamics
    • Figure 5.28: Focus therapy areas and revenue shares of AstraZeneca, 2007
    • Figure 5.29: Ticagrelor DISPERSE trial results
    • Figure 5.30: Major events/trends in AstraZeneca's forcasted growth dynamics
    • Figure 5.31: Focus therapy areas and revenue shares of Novartis, 2007
    • Figure 5.33: Major events/trends in Novartis's forcasted growth dynamics
    • Figure 5.34: Focus therapy areas and revenue shares of Merck, 2007
    • Figure 5.36: Major events/trends in Merck & Co's forcasted growth dynamics
    • Figure 5.37: Focus therapy areas and revenue shares of Bayer, 2007
    • Figure 5.38: Xarelto Phase III top-line data
    • Figure 5.39: Major events/trends in Bayer's forcasted growth dynamics
    • Figure 5.40: Focus therapy areas and revenue shares of GSK, 2007
    • Figure 5.41: Major events/trends in GSK's forcasted growth dynamics
    • Figure 5.42: Focus therapy areas and revenue shares of Servier, 2007
    • Figure 5.43: Major events/trends in Servier's forcasted growth dynamics
    • Figure 5.44: Focus therapy areas and revenue shares of Roche, 2007
    • Figure 5.45: Dalcetrapib Phase II trial data
    • Figure 5.46: Major events/trends in Roche's forcasted growth dynamics
    • Figure 5.47: Focus therapy areas and revenue shares of Boehringer Ingelheim, 2007
    • Figure 5.48: Major events/trends in Boehringer Ingelheim's forcasted growth dynamics
    • Table 2.1: Estimated prevalence of hypertension in the Asian region, 2007
    • Table 2.2: Estimated prevalence of hypertension in the Asian region,
    • Table 2.3: Interpretation of blood lipid levels
    • Table 2.4: Estimated prevalence of hypercholesterolemia in the Asian region, 2007
    • Table 2.5: Estimated forecast prevalence of hypercholesterolemia in the Asian region, 2008-14
    • Table 2.6: Estimated prevalence of diabetes in the Asian region, 2007
    • Table 2.7: Estimated prevalence of diabetes in the Asian region, 2008-14
    • Table 2.8: Estimated prevalence of major CV diseases in the Asian region, 2007
    • Table 2.9: Estimated incidence of myocardial infarction (MI) in the Asian region, 2007
    • Table 2.10: Estimated incidence of DVT in the Asian region, 2007
    • Table 2.11: Estimated prevalence of stroke in the Asian region, 2007
    • Table 3.12: Recent statistics on the healthcare sector in the Asian region, 2006
    • Table 3.13: Public and private financing in 10 Asian markets, 2005
    • Table 3.14: Sales of types of CV brands in the 10 major markets of the Asian region, 2007
    • Table 4.15: Breakdown of the Asian CV market by major therapeutic areas, 2006-07
    • Table 4.16: CV sales by therapy area across the Asian region, 2007
    • Table 4.17: Top five leading CV drug classes across 10 major Asian and global markets, 2007
    • Table 4.18: Top 10 Asian CV brands, 2006-07
    • Table 4.19: Top five leading brands across the 10 major Asian and global markets, 2007
    • Table 4.20: Breakdown of Asian antihypertensive market by drug class, 2006-07
    • Table 4.21: Breakdown of the Asian antihypertensive market by leading brands, 2006-08
    • Table 4.22: Market share of the leading classes of antihypertensives drugs in the Asian region,
  • 2007
    • Table 4.23: Breakdown of the CCB class in the Asian market by leading brands, 2006-07
    • Table 4.24: Breakdown of the ARB drug class in the Asian market by leading brands, 2006-07
    • Table 4.25: Breakdown of the ACE inhibitor class in the Asian market by leading brands, 2006-07
    • Table 4.26: Breakdown of the beta-blocker class in the Asian market by leading brands, 2006-07
    • Table 4.27: Breakdown of the diuretics class in the Asian market by leading brands, 2006-07
    • Table 4.28: Sales forecasts for antihypertensive drug classes in the major markets of the Asian region, 2008-14
    • Table 4.29: Breakdown of Asian antihypertensive market by drug class, 2006-07
    • Table 4.30: Breakdown of the Asian antihypertensive market by leading brands, 2006-07
    • Table 4.31: Market share of the leading classes of anti-dyslipidemic drugs in the Asian region, 2007
    • Table 4.32: Breakdown of the statins class in the Asian market by leading brands, 2006-07
    • Table 4.33: Sales forecasts for dyslipidemia drug classes in the Asian region, 2008-14
    • Table 4.34: Breakdown of Asian cardiac therapies market by drug class, 2006-07
    • Table 4.35: Breakdown of the cardiac therapies class in the Asian market by leading brands, 2006- 07
    • Table 4.36: Sales forecasts for cardiac therapies drug classes in the Asian region, 2004-10
    • Table 4.37: Breakdown of Asian anti-thrombotics market by drug class, 2006-07
    • Table 4.38: Breakdown of the Asian anti-thrombotics market by leading brands, 2006-07
    • Table 4.39: Breakdown of the oral anti-platelets class in the Asian market by leading brands, 2006-07
    • Table 4.40: Sales forecast for the anti-thrombotic drug class in the Asian region, 2008-14
    • Table 4.41: Key players in the Asian CV market, 2006-07
    • Table 5.42: Top five companies across the 10 major Asian and global markets, 2007
    • Table 5.43: Key asian markets for Pfizer, 2007
    • Table 5.44: Pfizer's marketed Asian CV portfolio, 2006-07
    • Table 5.45: Pfizer's CV R&D pipeline, 2008
    • Table 5.46: An overview of Apixaban
    • Table 5.47: Forecast sales for Pfizer's Asian CV portfolio, 2008-14
    • Table 5.48: Key asian markets for Sanofi-Aventis, 2007
    • Table 5.49: Sanofi-Aventis's marketed Asian CV portfolio, 2007
    • Table 5.50: Sanofi-Aventis's late stage CV R&D pipeline, 2008
    • Table 5.51: An overview of Multaq
    • Table 5.52: Multaq Phase III trial results
    • Table 5.53: Forecast sales for Sanofi-Aventis's Asian CV portfolio, 2008-14
    • Table 5.54: Key asian markets for AstraZeneca, 2007
    • Table 5.55: AstraZeneca's marketed Asian CV portfolio, 2006-07
    • Table 5.56: Sanofi-Aventis' late stage CV R&D pipeline, 2008
    • Table 5.57: An overview of ticagrelor
    • Table 5.58: Forecast sales for AstraZeneca's Asian CV portfolio, 2008-14
    • Table 5.59: Key asian markets for Novartis, 2007
    • Table 5.60: Novartis's marketed Asian CV portfolio, 2006-07
    • Table 5.61: Novartis's late stage CV R&D pipeline, 2009
    • Table 5.62: An overview of Tekturna/Rasilez
    • Table 1.1: ASPIRE HIGHER Phase III trial series
    • Table 5.63: Forecast sales for Novartis's Asian CV portfolio, 2008-14
    • Table 5.64: Key asian markets for Merck & Co, 2007
    • Table 5.65: Merck & Co's marketed Asian cardiovascular portfolio, 2006-07
    • Table 5.66: Merck's late stage CV R&D pipeline, 2008
    • Table 5.67: An overview of Anacetrapib
    • Table 5.68: Forecast sales for Meck & Co's Asian CV portfolio, 2008-14
    • Table 5.69: Key asian markets for Bayer, 2007
    • Table 5.70: Bayer's marketed Asian cardiovascular portfolio, 2007
    • Table 5.71: Bayer's cardiovascular R&D pipeline, 2008
    • Table 5.72: An overview of Xarelto
    • Table 5.73: Forecast sales for Bayer's Asian cardiovascular portfolio, 2008-14
    • Table 5.74: Key asian markets for GlaxoSmithKline, 2007
    • Table 5.75: GSK's marketed Asian cardiovascular portfolio, 2007
    • Table 5.76: GSK's cardiovascular R&D pipeline, 2008
    • Table 5.77: An overview of Letairis
    • Table 5.78: Forecast sales for GSK's Asian cardiovascular portfolio, 2008-14
    • Table 5.79: Key asian markets for Servier, 2007
    • Table 5.80: Servier's marketed Asian cardiovascular portfolio, 2007
    • Table 5.81: Forecast sales for Servier's Asian CV portfolio, 2008-14
    • Table 5.82: Key asian markets for Roche, 2007
    • Table 5.83: Roche's marketed Asian cardiovascular portfolio, 2007
    • Table 5.84: Roche's cardiovascular R&D pipeline, 2008
    • Table 5.85: Forecast sales for Roche's Asian CV portfolio, 2008-14
    • Table 5.86: Key asian markets for Boehringer Ingelheim, 2007
    • Table 5.87: Boehringer Ingelheim's marketed Asian cardiovascular portfolio, 2007
    • Table 5.88: Forecast sales for Boehringer Ingelheim's Asian CV portfolio, 2008-14
    • Table 5.89: Comparative ranking of key players in 2007 - 2014